Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Applications can be submitted via the online dedicated service only. Applications sent by fax or email will not be accepted.
Submission Deadline: Thursday 5 December 2019, 23:59 (Paris Time). No late submission will be accepted.
If you do not click on the submit button, your application will be saved in Draft Status. You will then be able to review it and submit it at a later time (but only before the deadline). NB: Applications that are in draft status after the deadline cannot be processed and therefore will not be considered for selection.
Once submitted, it is not possible to make any corrections to the application content or information (such as Presenter details, topic etc...). The ESC is not authorised to make changes to a submission. In order to correct your application you must withdraw it and submit a new corrected version prior to the deadline (See below for withdrawal procedure). Note that, such replacement of your application is not possible after the deadline. In the case of errors in your application discovered after the deadline, you may indicate the correction during the presentation at the congress.
If you want to withdraw an application already submitted, please notify us as quickly as possible at firstname.lastname@example.org stating the title of the application to be withdrawn. Note that, withdrawals are still accepted after the submission deadline.
You need to select the category in which your application best fits –
Select from the pre-defined topic list, the topic which best aligns with the technology’s application.
The Technologies & solutions should either be on the market, “ready for market” or in a late development stage.
Examples of technologies/approaches that can be illustrated with practical user cases, and ideally have outcome studies rather than just user numbers/satisfaction data, will be prioritised.
Please specify the medical device status – already certified medical device, certification as medical device in progress, or whether it is not a medical device.
This is the technology presentation title. If accepted, your technology will be presented to the audience with this title. 200 characters maximum
Sales and marketing presentation are not accepted.
You need to indicate the link of the presenter with the technology – Inventor, Developer, End-user, Product Manager or other
The EHRA Selection Committee is requesting that submitters disclose all information pertaining to commercial promotion of a proprietary product and/or support relation with Research or Commercial Companies.
You must disclose all sources of funding for your technology development and commercialisation including Full name(s) of the funding company/organisation.
This declaration is mandatory.
In your application, you will need to indicate who will use your technology: Patient, Doctors, Allied Professions/Nurses, data Collection or Researchers and describe its use (600 characters maximum)
The submitter is automatically listed as contributor of the application. If the submitter is not the presenter, she/he will be asked to enter the information related to the presenter, who will be contacted upon results announcement for all information required for the presentation.
We recommend you use the following structure to describe your technology in clearly identified sections 1500 characters maximum:
You must upload a PDF file showing a case illustration – demonstration of use for the technology. You can upload up to 2 pages.
Images can be included on the PDF file. Maximum size 10 Mb.
If using a clinical case, ensure that no patient identification data are shown.
The EHRA Selection Committee will evaluate the Applications using the following Criteria.
Selection Criteria will consider
Submission of an application constitutes a commitment to present if accepted. Failure to present and register, if not justified, will be identified as “no-show” and will jeopardize future acceptance of applications.
Results will be announced by late December.
Submitter represents and warrants to the ESC that he/she/they is/are authorized to submit and present the technology and that the submission does not infringe upon any copyright, proprietary or personal right of any third party and/or any confidentiality obligations. The submitter hereby affirms that the work submitted is based on thorough examination and investigation for accurateness.
If the application is accepted for presentation, the presenter will be asked to transfer and assign to the ESC free of charge, on a non-exclusive and worldwide basis, for fifteen years from the present submission the rights to edit, publish, reproduce, reformat, distribute in whole or in part the presentation given and prepare all type of derivative works such as press releases and/or educational products, using all communication tools and means, now known or hereinafter developed, including any and all digital means and any and all supports or forms of media, now known or hereinafter developed, in particular all paper, analog, digital, numerical and electronic media, including Internet, Intranet and Extranet sites and social media. This includes use in indexes or search databases in print, electronic, or other media.
The submitter signs for all Stakeholders that He/she accepts responsibility for the present rules for submission and presentation.
The ESC requests all Presenters to display a slide at the beginning of their presentation indicating disclosure information as applicable. This will allow the audience to take potential conflicts of interest into account when assessing the objectivity of the presentation.
A potential conflict of interest may arise from various relationships, past or present, such as employment, consultancy, investments and stock ownership, funding for research, family relationship, etc.
This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the article. Such relationships include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standing advisory council or committee, being on the board of directors, or being publicly associated with the company or its products. Other areas of real or perceived conflict of interest could include receiving honoraria or consulting fees or receiving grants or funds from such corporations or individuals representing such corporations.
By certifying that you have read and accepted these Submission rules, you also confirm having received the prior approval from all contributors and stakeholders to provide their data to the ESC.
The information collected in this Call for Technology & Innovation is subject to data processing to proceed with the elaboration of ESC scientific programmes.
The recipients of the data are ESC Staff who process the submissions and the ESC Committees and volunteers involved in the scientific programme.
Data collected will be kept for 20 years.
Transfer of personal data to ESC Staff, contractors as well as other ESC related scientific organisations occurs for production, promotion and dissemination of the Content.
In accordance with the chapter 3 of the European Regulation 2016/679 with regards to data protection, you have the right to request from ESC, access to and rectification or erasure of your personal data or restriction of processing concerning your data or to object to processing as well as the right to data portability. This is done thru withdrawal of the submission according to the terms and conditions of withdrawal.
For such, please contact (together with a proof of identity):
European Society of Cardiology
2035 Route des Colles
CS 80179 Biot
06903 SOPHIA ANTIPOLIS CEDEX, France
Or by email to email@example.com
You have the right to lodge a complaint with a supervisory authority, and for information, ESC has appointed a Data Protection Officer that you can reach at firstname.lastname@example.org
All the rules pertaining to the present submission are governed by and construed in accordance with the laws of France without regard to any conflicts of laws principles thereof that would require the application of the law of any other jurisdiction. Any disputes arising in relation hereto shall be submitted to the exclusive jurisdiction of the French Tribunal de Grande Instance located in Grasse, France.
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.